Patients with metastatic colorectal cancer (CRC) with disease progression on first-line 5-fluorouracil-based chemotherapy regimens typically receive alternative chemotherapy regimens, including trifluridine plus tipiracil (FTD–TPI), although the effectiveness of combining targeted therapies with this regimen remains uncertain. Now, data from the phase III SUNLIGHT trial demonstrate improved outcomes with the addition of bevacizumab to FTD–TPI.